HER2 ADC Design Has Moved Beyond Target Binding: Why ADC Payload Delivery Now Defines Efficacy

For most of the ADC field's history, target binding was treated as the primary engineering challenge: find the right antigen, build a high-affinity antibody, and attach a cytotoxic payload. In HER2-targeted oncology, that paradigm is no longer sufficient. The tumors that resist modern HER2-directed constructs are not always HER2-negative; they are often tumors where the delivered payload fails to reach, penetrate, or persist within the target tissue. The clinical and preclinical evidence increasingly points to ADC payload delivery architecture, not antigen affinity alone, as the defining variable in program success or failure.

Why ADC Payload Delivery Has Become the Central Design Problem

The mechanistic rationale for this shift is now well documented. A 2026 review in Current Opinion in Obstetrics and Gynecology described second-generation HER2-targeted ADCs as constructs whose clinical potency depends critically on three delivery-level variables: a cleavable linker, a high drug-to-antibody ratio, and a membrane-permeable payload capable of acting beyond the directly targeted cell. None of these features are properties of antibody binding; all are properties of how the construct behaves after it reaches the tumor.

The implications extend to tumors with low or heterogeneous HER2 expression. A 2025 study published in Nature Communications reported that a leading HER2-targeted ADC can release its payload extracellularly through a cathepsin L-dependent mechanism, generating cytotoxicity in HER2-low and HER2-negative breast cancer models in vivo. That finding reframes the question entirely: payload activity in the tumor microenvironment, not receptor engagement alone, governs therapeutic reach. The bystander effect, in which released payload diffuses into the surrounding microenvironment and kills neighboring HER2-low or HER2-negative cells, is now recognized as a meaningful contributor to clinical response in heterogeneous tumors.

Resistance biology reinforces the same conclusion. Resistance can arise from impaired internalization, altered intracellular trafficking, payload efflux pumps, or DNA damage response adaptation. These are payload delivery failures, not target binding failures, and they require payload-level solutions.

Dual Payloads and the Next Generation of ADC Payload Delivery Architecture

One of the most consequential responses to the delivery challenge is the move toward dual-payload ADC design. Rather than delivering a single cytotoxic mechanism, dual-payload constructs aim to address tumor heterogeneity and resistance simultaneously by co-delivering complementary agents to the same tumor site.

Preclinical evidence for this approach is accumulating. A 2025 publication in ACS Medicinal Chemistry Letters described a homogeneous trastuzumab-based dual-payload ADC combining MMAE and a topoisomerase I inhibitor at a drug-to-antibody ratio of 10, reporting superior in vitro cytotoxicity in HER2-positive cells and enhanced tumor suppression in a xenograft model compared to a single-payload benchmark construct. The clinical translation of this concept is now underway: in March 2026, Callio Therapeutics reported first-patient dosing for CLIO-8221, a HER2-directed dual-payload ADC combining a topoisomerase I inhibitor with an ATR inhibitor, designed to co-deliver orthogonal DNA damage mechanisms to HER2-expressing solid tumors.

Guidant BioTherapeutics is pursuing a related logic in its preclinical ADC program. GDT-101, a dual-payload ADC combining a HER2-targeting antibody with both MMAE and a topoisomerase I inhibitor, is designed to address HER2-positive breast and lung cancer with complementary cytotoxic mechanisms delivered to the same tumor site. The strategic premise reflects the same field-wide recognition: ADC payload delivery architecture, including payload class selection and co-delivery design, is now as important as target selection. Guidant's broader navigated delivery platform is built on this principle, using albumin-mediated tumor accumulation to enhance intratumoral drug concentration and retention across its therapeutic candidates.

Linker Chemistry, Microenvironmental Release, and the Limits of Traditional Metrics

Linker design sits at the intersection of efficacy and safety in any ADC program. Cleavable linkers that respond to lysosomal proteases or microenvironmental conditions can broaden payload activity but introduce the risk of premature systemic release if the linker is not sufficiently selective. The cathepsin L-dependent extracellular release mechanism identified in the 2025 Nature Communications study illustrates that this is not a theoretical risk: payload release occurs in the tumor microenvironment, mediated by endogenous proteases, and contributes meaningfully to efficacy. Managing where and when release occurs is therefore a central engineering variable, not a secondary consideration.

This focus on microenvironmental biology aligns with a broader principle in Guidant's pipeline strategy. The FHAB platform exploits FcRn-mediated albumin recycling to concentrate therapeutic payloads in tumors and inflamed tissues, leveraging the same microenvironmental dynamics that now define ADC payload delivery optimization. In Guidant's clinical program, GDT-001, an IL-12 fusion candidate in Phase 1 evaluation in advanced solid tumors, the goal is not only to deliver cytokine activity to the tumor but to sustain it there long enough to engage the immune microenvironment, a navigated delivery objective that mirrors the field's evolving thinking on intratumoral drug exposure.

Traditional metrics based on receptor binding affinity or systemic pharmacokinetics do not fully capture intratumoral drug exposure, extracellular release dynamics, or bystander killing reach. As the HER2 ADC field continues to mature, development decisions are increasingly being made on the basis of payload-level endpoints, microenvironmental behavior, and resistance coverage, criteria that demand a fundamentally different design framework than antibody engineering alone.

Implications for Platform Strategy and Partnership Evaluation

For BD executives and oncology investors evaluating HER2-targeted ADC programs, the field's reorientation toward ADC payload delivery has direct implications for how platform differentiation should be assessed. Programs that can demonstrate superior intratumoral drug exposure, controlled linker behavior, resistance-informed payload selection, and manufacturable dual-payload architecture are now positioned more favorably than those competing solely on antibody affinity or HER2 expression criteria.

The manufacturability question is not trivial. Higher drug-to-antibody ratios, dual conjugation strategies, and optimized linker systems improve function but complicate synthesis, stability assessment, and regulatory characterization. Platforms that can address delivery quality without sacrificing manufacturing tractability represent a genuine competitive distinction.

Guidant BioTherapeutics is advancing its pipeline of navigated delivery candidates on the thesis that delivery architecture is the shared determinant of therapeutic success across cytokine immunotherapy and ADC modalities. Whether the payload is a cytokine, a microtubule inhibitor, or a topoisomerase poison, the core challenge is the same: get an active therapeutic to the tumor, keep it there, and limit systemic exposure. That mission connects GDT-001 in the clinic to GDT-101 in preclinical development, and it reflects the same scientific logic now reshaping the HER2 ADC landscape.

To learn more about the scientific principles behind Guidant's approach to tumor-selective payload delivery, visit the FHAB Technology page.

References

1. Callio Therapeutics Doses First Patient in Phase I Clinical Trial of Dual-Payload ADC CLIO-8221 in Advanced HER2-Expressing Solid Tumors — BioSpace

2. Trastuzumab deruxtecan and the evolving role of human epidermal growth factor receptor 2 in advanced breast cancer — PubMed / Current Opinion in Obstetrics and Gynecology

3. Homogeneous Dual-Payload Antibody-Drug Conjugates Produced by Combined Distinct Conjugation Strategies — ACS Medicinal Chemistry Letters

4. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd) — Nature Communications